Merck (MRK) Announces Positive Recommendation from EU Medicines Agency

​Merck & Co., Inc. (NYSE:MRK) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 19, Merck & Co., Inc. (NYSE:MRK) announced that its ENFLONSIA has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

​The approval is for preventing respiratory syncytial virus lower respiratory tract disease in newborns and infants during their first RSV season. Management noted that they now await review by the European Commission for marketing authorization in the EU, Iceland, Liechtenstein, and Norway, with a final decision expected by the end of 2025.

​The endorsement is based on results from two clinical trials, CLEVER and SMART, which showed ENFLONSIA significantly reduced RSV infections and hospitalizations compared to placebo.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company that develops and sells prescription medicines, vaccines, and biologic therapies for human health.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.